Protective Effect of Polydeoxyribonucleotide Against Renal Ischemia-Reperfusion Injury in Mice.

Abstract

BACKGROUND:

Polydeoxyribonucleotide (PDRN) is an A2A receptor agonist that induces vascular endothelial growth factor (VEGF) production during the pathological condition of low tissue perfusion. Ischemia-reperfusion injury (IRI) is a major problem after renal transplantation. In the present study, we investigated whether PDRN exhibits reno-protective effects against ischemia-reperfusion-induced acute kidney injury in mice.

METHODS:

Renal ischemia-reperfusion injury was induced in male C57BL/6 mice by bilateral renal pedicle occlusion for 30 minutes, followed by reperfusion for 48 hours. PDRN (8 mg/kg body weight intraperitoneally) was administered 30 minutes before IRI.

RESULTS:

Treatment with PDRN significantly decreased neutrophil gelatinase-associated lipocalin levels in the urine, blood urea nitrogen level, and serum creatinine levels as well as kidney tubular injury. Western blotting showed that PDRN significantly increased the levels of vascular endothelial growth factor and B-cell lymphoma protein and attenuated p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, inducible nitric oxide synthase, and Bcl-2-associated X protein levels 48 hours after IRI.

CONCLUSIONS:

Our findings suggest that PDRN is a potential therapeutic agent for acute ischemia-induced renal damage.

• Authors: E K Jeong, H J Jang, S S Kim, S Y Lee, M Y Oh, H J Kim, D W Eom, J Y Ham, D J Han
• Journal: Transplantation proceedings (Transplant Proc) Vol. 48 Issue 4 Pg. 1251-7 (May 2016) ISSN: 1873-2623 [Electronic] United States
• PMID: 27320598 (Publication Type: Journal Article)
• Copyright: Copyright © 2016 Elsevier Inc. All rights reserved.

Chemical References

• Biomarkers
• Polydeoxyribonucleotides
• Protective Agents

Topics

• Acute Kidney Injury (diagnosis, etiology, metabolism, prevention & control)
• Animals
• Biomarkers (metabolism)
• Kidney Transplantation
• Male
• Mice
• Mice, Inbred C57BL
• Polydeoxyribonucleotides (therapeutic use)
• Protective Agents (therapeutic use)
• Random Allocation
• Reperfusion Injury (diagnosis, metabolism, prevention & control)
• Treatment Outcome